Piper remain buyers of Audentes after update on AT132

Piper Jaffray analyst Christopher Raymond said he remains a buyer of Audentes Therapeutics after the company announced new interim data from ASPIRO, the Phase 1/2 clinical trial of AT132 for the treatment of X-linked Myotubular Myopathy. Significant improvements in respiratory function continued for all patients in Cohort 1 and across the board CHOP-INTEND scores tended to improve for most patients, Raymond tells investors. The analyst, who thinks the XLMTM program has become “increasingly derisked,” maintains an Overweight rating on Audentes shares.
https://thefly.com/landingPageNews.php?id=2800549